6 News & Press Releases found
Zetagen Therapeutics Inc. News
-
ZetaMetâ„¢ Receives Health Canada Authorization for Phase 2a Study in Treating Metastatic Bone Lesions
Technology is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone Study will examine the safety and efficacy of ZetaMetTM in the treatment of metastatic bone lesions as part of advanced stage ...
-
ZetaMetâ„¢ Receives Breakthrough Device Designation from U.S. Food and Drug Administration (FDA) for Treatment of Metastatic Bone Cancers
The technology is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone Zetagen Therapeutics is developing the therapy for patients living with metastatic bone lesions and other osteologic conditions ...
-
Zetagen Therapeutics, Inc. Announces European Patent for the Treatment of Stimulating Bone Growth
U.S.-based biopharmaceutical company has discovered and patented a novel molecular pathway intended to treat metastatic bone lesions Latest patent issuance follows previous patents for methods in stimulating bone growth, promote controlled bone ...
-
Zetagen Therapeutics, Inc. Receives Australian Patent Issuance for Treatment of Stimulating Bone Growth
U.S.-based biopharmaceutical company has discovered and patented a novel molecular pathway intended to treat metastatic bone lesions Latest patent issuance furthers the Company’s Global IP strategy Company’s intellectual property ...
-
Zetagen Therapeutics, Inc. Receives Patent for Regulation of Bone Growth and Bone Degradation Using Small-Molecule
U.S.-based biopharmaceutical company has discovered and patented a novel molecular pathway intended to treat metastatic bone lesions Latest patent issuance follows previous patents for methods in stimulating bone growth using ZetaMet™ ...
-
Zetagen Therapeutics, Inc. Receives Patents for Methods in Stimulating Bone Growth Using Small-Molecule
U.S.-based biopharmaceutical company has discovered and patented a novel molecular pathway intended to treat metastatic bone lesions Latest patent issuance furthers the Company’s Global IP strategy Company’s intellectual property ...